Method of impairing movement of a CLA + memeory T-cell within or to the skin of a mammal by administering a CTACK antagonist

US6824781B2 · kind B2 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Wei Wang · Beijing, CN
• Elizabeth Oldham · Santa Clara, US
• Hortensia Soto · San Diego, US
• Ying Liu · Mountain View, US
• Susan A. Hudak · Redwood City, US
• Bernhard Homey · Düsseldorf, DE
• Janine M. Morales · San Francisco, US
• Sirid-Aimee Kellermann · Palo Alto, US
• Leslie McEvoy · Mountain View, US
• Edward Bowman · Redwood City, US
• Albert Zlotnik · Palo Alto, US

Key dates

• Filing date: Jul 2, 2001
• Grant date: Nov 30, 2004
• Expiry date: Jul 2, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/505
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Agonists or antagonists of CTACK or Vic chemokines, and various methods of use in dermatological and related applications are provided. In particular, the method makes use of fact that the CTACK or Vic chemokines are specifically capable of inducing movement of a skin cell subset. Moreover, matching of ligand with GPR2 receptor in mammals provides methods of use.